here are your price targets if we get lucky or whatever
there are more targets but i'm a chart genie and have done the research on phase 2 blockbuster valuation multiples and the mss-crc market potential and other factors to run the numbers.
any move of consequence at the least establishes a .54 floor. and then $1.30 is a relatively easy move if this has data that puts it towards the edge of greatness. momo or really good data has 2.54 and 3.00 in sight. please, read on, don't cringe.
beyond that, other then temp momo pushes, are the potential for buyout valuations of $5 and $10 and $15b. lol i have ATTACKED you all for YEARS for daring to attach ridiculous valuations... but here i am doing it. if this gets bought out on phase 2 data, which is very common, basically the default, then it will be based almost solely on mss-crc and perhaps tnbc. $5b is sad. $10b i believe becomes almost automatic and $15b is my high end pie ion the sky number.
that's $3.90 and $7.80 and $12.70 per share.
the historical chart has a very nice 3.85 - 3.90 target and a weaker 7.70 target.
lol, for now i am only allowing myself to EXPECT $1.30 on decent data, but i also expect the next couple levels up to $3.00 to at least be in play via the momo trades on a temporary basis... following good enough data...
NEED GOOD DATA FIRST!
MSS-CRC is tough. it has defenses not seen in all but a couple other cancers. but, at the same time, ccr5 is a factor in several of the difficult challenges that it poses. i expect results to certainly not be as strong as tnbc, but the bar is so very low in mss-crc and ccr5 plays a big role.
that old crc data is a huge fall back for me mentally, knowing that they had activity that indicates a pretty good possibility of turning out eye opening results.
the double shot of mss-crc combo and mss-crc hot to cold is also nice to look forward to. both would be awesome but at the same time they only need 1 of them.
i do not care at all about tnbc trials alzheimers latch or almost anything else tbh. the tnbc retrospective data i care about. the upcoming trial i don't care about. anything that is coming as far as pharma interest will play out prior to that if the mss-crc data is good enough.
1 HUGE sleeper is the liver mets pilot. liver mets is sort of the gatekeeper for metastatic mss-crc treatment failure. the liver mets depletes the t-cells. but ccr5 is central to that process, and shitty ccr5 inhibitors long ago showed positive signals in mss-crc liver mets in failed keytruda combo trials.
FORGET about approvals. FORGET about manufacturing process validation. FORGET about the hiv triple therapy prospect. FORGET about timelines. FORGET about it all. strong MSS-CRC data will lead to a swift end to this journey imo.
need to strike while the mss-crc moat exists. new shit will come down the pike, eventually. if pharma wishes to buy, cytodyn is going to sell. the price will be right, by every historical measure.
i sound like idiotic UWS here. but the time has come. lol, NEED THAT DATA!
there are more targets but i'm a chart genie and have done the research on phase 2 blockbuster valuation multiples and the mss-crc market potential and other factors to run the numbers.
any move of consequence at the least establishes a .54 floor. and then $1.30 is a relatively easy move if this has data that puts it towards the edge of greatness. momo or really good data has 2.54 and 3.00 in sight. please, read on, don't cringe.
beyond that, other then temp momo pushes, are the potential for buyout valuations of $5 and $10 and $15b. lol i have ATTACKED you all for YEARS for daring to attach ridiculous valuations... but here i am doing it. if this gets bought out on phase 2 data, which is very common, basically the default, then it will be based almost solely on mss-crc and perhaps tnbc. $5b is sad. $10b i believe becomes almost automatic and $15b is my high end pie ion the sky number.
that's $3.90 and $7.80 and $12.70 per share.
the historical chart has a very nice 3.85 - 3.90 target and a weaker 7.70 target.
lol, for now i am only allowing myself to EXPECT $1.30 on decent data, but i also expect the next couple levels up to $3.00 to at least be in play via the momo trades on a temporary basis... following good enough data...
NEED GOOD DATA FIRST!
MSS-CRC is tough. it has defenses not seen in all but a couple other cancers. but, at the same time, ccr5 is a factor in several of the difficult challenges that it poses. i expect results to certainly not be as strong as tnbc, but the bar is so very low in mss-crc and ccr5 plays a big role.
that old crc data is a huge fall back for me mentally, knowing that they had activity that indicates a pretty good possibility of turning out eye opening results.
the double shot of mss-crc combo and mss-crc hot to cold is also nice to look forward to. both would be awesome but at the same time they only need 1 of them.
i do not care at all about tnbc trials alzheimers latch or almost anything else tbh. the tnbc retrospective data i care about. the upcoming trial i don't care about. anything that is coming as far as pharma interest will play out prior to that if the mss-crc data is good enough.
1 HUGE sleeper is the liver mets pilot. liver mets is sort of the gatekeeper for metastatic mss-crc treatment failure. the liver mets depletes the t-cells. but ccr5 is central to that process, and shitty ccr5 inhibitors long ago showed positive signals in mss-crc liver mets in failed keytruda combo trials.
FORGET about approvals. FORGET about manufacturing process validation. FORGET about the hiv triple therapy prospect. FORGET about timelines. FORGET about it all. strong MSS-CRC data will lead to a swift end to this journey imo.
need to strike while the mss-crc moat exists. new shit will come down the pike, eventually. if pharma wishes to buy, cytodyn is going to sell. the price will be right, by every historical measure.
i sound like idiotic UWS here. but the time has come. lol, NEED THAT DATA!
9
4
